Company: MBIO
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001558370-25-003913
Chunk: 15

Company: MUSTANG BIO, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 15E
Chunk 15
---
Item 15.     Exhibits, Financial Statement Schedules

​

(a) Financial Statements.

The following financial statements are filed as part of this Form 10-K:

​

Report of Independent Registered Public Accounting Firm (KPMG LLP, New York, NY; PCAOB ID: 185)F-2  Financial Statements: Balance Sheets as of December 31, 2024 and 2023F-4Statements of Operations for the Years Ended December 31, 2024 and 2023F-5Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2024 and 2023F-6Statements of Cash Flows for the Years Ended December 31, 2024 and 2023F-7Notes to Financial StatementsF-8 - F-29

​

(b) Exhibits.

​

Exhibit No. Description1.1​At Market Issuance Sales Agreement, dated July 27, 2018, between the Company, B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation, and Oppenheimer & Co. Inc. (incorporated by reference to the Exhibit 1.1 of the Registrant’s Current Report on Form 8-K (File No. 001-38191) filed with the SEC on July 27, 2018).​1.2​Amendment No. 1 to At Market Issuance Sales Agreement, dated July 20, 2020, between the Company, B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation and Oppenheimer & Co. Inc. (incorporated by reference to the Exhibit 1.2 of the Registrant’s Current Report on Form 8-K (File No. 001-38191) filed with the SEC on July 24, 2020).​